6216-61-1

Basic information

• Product Name: (S)-benzyl 1-hydroxy-4-Methylpentan-2-ylcarbaMate
• Synonyms: (S)-benzyl 1-hydroxy-4-Methylpentan-2-ylcarbaMate;CarbaMic acid, [(1S)-1-(hydroxyMethyl)-3-Methylbutyl]-, phenylMethyl ester;N-[(1S)-1-(hydroxymethyl)-3-methylbutyl]-Carbamic acid, phenylmethyl ester;N-Benzyloxycarbonyl-L-leucinol
• CAS NO: 6216-61-1
• Molecular Formula: C₁₄H₂₁NO₃
• Molecular Weight: 251.32144
• Mol File: 6216-61-1.mol
• Article Data: 37

Chemical Properties

• Appearance: /
• Density: 1.083
• CAS DataBase Reference: (S)-benzyl 1-hydroxy-4-Methylpentan-2-ylcarbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-benzyl 1-hydroxy-4-Methylpentan-2-ylcarbaMate(6216-61-1)
• EPA Substance Registry System: (S)-benzyl 1-hydroxy-4-Methylpentan-2-ylcarbaMate(6216-61-1)

Safety Data

• Hazardous Substances Data: 6216-61-1(Hazardous Substances Data)

Usage

Description

(S)-Benzyl 1-hydroxy-4-Methylpentan-2-ylcarbaMate, a carbamate derivative with the molecular formula C16H23NO3, features a benzyl group attached to hydroxy and methylpentan-2-yl groups. This chemical compound is likely to possess pharmaceutical applications due to its structural characteristics, as carbamate derivatives are known for their diverse biological activities. The presence of a benzyl group may also contribute to the compound's solubility and stability, making it a potential candidate for use in the pharmaceutical industry.

Uses

Used in Pharmaceutical Industry:
(S)-Benzyl 1-hydroxy-4-Methylpentan-2-ylcarbaMate is used as a pharmaceutical ingredient for its potential biological activities. The carbamate structure and benzyl group may contribute to its effectiveness in various therapeutic applications.
Used in Drug Synthesis:
(S)-benzyl 1-hydroxy-4-Methylpentan-2-ylcarbaMate can also be utilized as a starting material for the synthesis of new drugs. Its unique structure may provide a foundation for the development of novel pharmaceuticals with specific therapeutic targets.
Further research and experimentation are necessary to fully comprehend the properties and potential applications of (S)-benzyl 1-hydroxy-4-Methylpentan-2-ylcarbaMate, as its current understanding is based on its structural features and the known activities of similar compounds.

Upstream product

• 70853-26-8 N-carbobenzoxy-L-leucinal 
• 7533-40-6 (S)-2-amino-4-methylpentan-1-ol 
• 501-53-1 benzyl chloroformate 
• 125814-24-6 Z-Leu-NCA 
• 58889-73-9 (S)-N-benzyloxycarbonyl-leucine ethyl ester 
• 24123-12-4 1-(benzyloxycarbonyl)-3-methylimidazolium chloride 
• 66866-66-8 phenylmethyl (4S)-4-(2-methylpropyl)-5-oxo-1,3-oxazolidine-3-carboxylate 
• 3397-35-1 Z-L-leucine hydroxysuccinimide ester 
• 2018-66-8 Z-Leu-OH 
• 61-90-5 L-leucine 
• 2743-40-0 L-leucine ethyl ester hydrochloride 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 51021-87-5 N-benzyloxycarbonyl-L-leucine methyl ester 
• 1235475-86-1 C₁₆H₂₃NO₄ 

Downstream Products

• 142056-20-0 Z-LeuΨ(CH2O)Gly-OCH3 
• 142056-21-1 Z-LeuΨ(CH2O)Gly-OC2H5 
• 2018-66-8 Z-Leu-OH 
• 28862-79-5 Z-D-Leu-OH 
• 70853-26-8 N-carbobenzoxy-L-leucinal 
• 162334-20-5 (L)-N-benzyloxycarbonyl-2-amino-4-methyl-pentyl-hexanoate 
• 7533-40-6 (S)-2-amino-4-methylpentan-1-ol 
• 1054645-97-4 Phenoxy-acetic acid (2R,3R,4R,5R)-5-[((S)-2-benzyloxycarbonylamino-4-methyl-pentyloxy)-hydroxy-phosphoryloxymethyl]-4-(2-phenoxy-acetoxy)-2-[6-(2-phenoxy-acetylamino)-purin-9-yl]-tetrahydro-furan-3-yl ester 
• 228557-24-2 benzyl N-[1-(azidomethyl)-3-methylbutyl]carbamate 
• 944261-74-9 C₂₀H₂₆N₄O₆ 
• 241149-73-5 (2'R,3'S)-methyl 2-[3-(benzyloxycarbonylamino)-2-hydroxybutyl]propenoate 
• 239135-75-2 (5S,1'S)-5-[1-(benzyloxycarbonylamino)-3-methylbutyl]-3-methylenedihydro-2(3H)-furanone 
• 241149-78-0 (2'S,3'S)-methyl 2-[3-(benzyloxycarbonylamino)-2-hydroxy-5-methylhexyl]propenoate 
• 6216-67-7 Adenosin-5'-phosphorsaeure-(N-benzyloxycarbonyl-L-leucinolat) 

Relevant articles and documents

SuFExable Isocyanides for Ugi Reaction: Synthesis of Sulfonyl Fluoro Peptides

Herein, the sulfonyl fluoro isocyanides were first developed as a new type of SuFExable synthon, and they are used as building blocks in the Ugi reaction (U-4CR). The Ugi reaction was established and the substrate scope was investigated, and various sulfonyl fluoro α-amino amides and peptides could be reached in a one-step synthesis. Therefore, this protocol opens a new vision for SuFExable building blocks and click chemistry, and it also provides a distinct approach to sulfonyl fluoro peptides.

Staudinger/aza-Wittig reaction to access Nβ-protected amino alkyl isothiocyanates

A unified approach to access Nβ-protected amino alkyl isothiocyanates using Nβ-protected amino alkyl azides through a general strategy of Staudinger/aza-Wittig reaction is described. The type of protocol used to access isothiocyanates depends on the availability of precursors and also, especially in the amino acid chemistry, on the behavior of other labile groups towards the reagents used in the protocols; fortunately, we were not concerned about both these factors as precursor-azides were prepared easily by standard protocols, and the present protocol can pave the way for accessing title compounds without affecting Boc, Cbz and Fmoc protecting groups, and benzyl and tertiary butyl groups in the side chains. The present strategy eliminates the need for the use of amines to obtain title compounds and thus, this method is step-economical; additional advantages include retention of chirality, convenient handling and easy purification. A few hitherto unreported compounds were also prepared, and all final compounds were completely characterized by IR, mass, optical rotation, and 1H and 13C NMR studies.

Synthesis and evaluation of chirally defined side chain variants of 7-chloro-4-aminoquinoline to overcome drug resistance in malaria chemotherapy

A novel 4-aminoquinoline derivative [(S)-7-chloro-N-(4-methyl-1-(4-methyl-piperazin-1-yl)pentan-2-yl)-quinolin-4-amine triphosphate] exhibiting curative activity against chloroquine-resistant malaria parasites has been identified for preclinical development as a blood schizonticidal agent. The lead molecule selected after detailed structure-activity relationship (SAR) studies has good solid-state properties and promising activity against in vitro and in vivo experimental malaria models. The in vitro absorption, distribution, metabolism, and excretion (ADME) parameters indicate a favorable drug-like profile.